Goodwin Procter LLP advised Aura Biosciences on the deal.
Aura Biosciences announced the closing of its oversubscribed $80 million financing. The financing was led by Matrix Capital Management and Surveyor Capital with participation from new investors, including Rock Springs Capital, Adage Capital Management LP and Velosity Capital. Existing investors Medicxi, Advent Life Sciences, Lundbeckfonden Ventures, Arix Bioscience, Chiesi Ventures, Ysios Capital and Columbus Venture Partners also participated in the round.
The company plans to use the proceeds from this financing to advance the clinical development of its VDC technology platform, including the pivotal Phase 3 program for AU-011, Aura’s lead candidate in development for the first line treatment of choroidal melanoma, and ongoing research for additional programs in ocular oncology, as well as expanding the VDC technology into bladder cancer, the first non-ophthalmic solid tumor indication.
Aura Biosciences is a clinical-stage oncology company developing a novel technology platform based on virus-like drug conjugates (VDCs) to target and destroy cancer cells selectively while activating the immune system to create long lasting anti-tumor immunity.
The Goodwin team was led by Danielle Lauzon (Picture), Stuart Cable, Stephanie Richards, Dan Hughes, Karin Yoo and Jai Kalra.
Involved fees earner: Stuart Cable – Goodwin Procter; Daniel Hughes – Goodwin Procter; Jaidev Kalra – Goodwin Procter; Danielle Lauzon – Goodwin Procter; Stephanie Richards – Goodwin Procter; Karin Yoo – Goodwin Procter;
Law Firms: Goodwin Procter;
Clients: Aura Biosciences;